Analyst Ratings For Obalon Therapeutics (NASDAQ:OBLN)
Today, Canaccord Genuity reiterated its Positive rating on Obalon Therapeutics (NASDAQ:OBLN) with a price target of $11.00.
Some recent analyst ratings include
- 1/22/2018-Canaccord Genuity Reiterated Rating of Positive .
- 11/16/2017-BTIG Research Reiterated Rating of Buy.
- 11/3/2017-Northland Securities Reiterated Rating of Sell.
- 10/31/2016-Stifel Nicolaus initiated coverage with a Buy rating.
Recent Insider Trading Activity For Obalon Therapeutics (NASDAQ:OBLN)
Obalon Therapeutics (NASDAQ:OBLN) has insider ownership of 16.40% and institutional ownership of 44.22%.
- On 10/12/2016 Kim P Kamdar, Director, bought 13,400 with an average share price of $15.00 per share and the total transaction amounting to $201,000.00.
- On 10/12/2016 Matthew Norwood, VP, bought 1,000 with an average share price of $15.00 per share and the total transaction amounting to $15,000.00.
Recent Trading Activity for Obalon Therapeutics (NASDAQ:OBLN)
Shares of Obalon Therapeutics closed the previous trading session at 5.18 down -0.05 1.05% with 5.25 shares trading hands.